Novel vaccination strategies based on recombinant Mycobacterium bovis BCG

International Journal of Medical Microbiology

Volumn 292, Issue 7-8, 2003, Pages 441-451

  Dietrich, Guido ^a   Viret, Jean Francois ^a   Hess, Jürgen ^b  

^a Berna Biotech AG   (Switzerland)

^b November AG   (Germany)

Author keywords

BCG vaccine; Heterologous antigen expression; Tuberculosis

Indexed keywords

ANTIGEN; BCG VACCINE; CALGRANULIN; DIPHTHERIA TOXIN; DRUG CARRIER; E7 ANTIGEN; GAG PROTEIN; GP63 ANTIGEN; MSP1 ANTIGEN; NEF PROTEIN; PERTUSSIS TOXIN; POL PROTEIN; RECOMBINANT ANTIGEN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ANTIGEN EXPRESSION; ANTIGENICITY; AUXOTROPHIC MUTANT; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BCG VACCINATION; CELL COMPARTMENTALIZATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; GENOME ANALYSIS; HUMAN; IMMUNE RESPONSE; IMMUNITY; INFECTION PREVENTION; INFECTION RESISTANCE; MICROBIAL ATTENUATION; MYCOBACTERIUM BOVIS; NONHUMAN; PROTECTION; SHORT SURVEY; TUBERCULOSIS;

EID: 0036488818     PISSN: 14384221     EISSN: None     Source Type: Journal    
DOI: 10.1078/1438-4221-00227     Document Type: Short Survey

References (85)

1. Abdelhak, S., Louzir, H., Timm, J., Blel, L., Benlasfar, Z., Lagranderie, M., Gheorghiu, M., Dellagi, K., Gicquel, B.: Recombinant BCG expressing the Leishmania surface antigen Gp63 induces protective immunity against Leishmania major infection in BALB/c mice. Microbiology 141, 1585-1592 (1995).
2. Abomoelak, B., Huygen, K., Kremer, L., Turneer, M., Locht, C.: Humoral and cellular immune responses in mice immunized with recombinant Mycobacterium bovis Bacillus Calmette-Guerin producing a pertussis toxin-tetanus toxin hybrid protein. Infect. Immun. 67, 5100-5105 (1999).
3. Aldovini, A., Young, R. A.: Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines. Nature 351, 479-482 (1991).
4. Aldovini, A., Young, R. A.: Recombinant BCG vaccines. In: Intracellular Bacterial Vaccine Vectors: Immunology, Cell Biology and Genetics (Y. Paterson, ed.), pp. 151-170. John Wiley & Sons, New York, Chichester, Weinheim, Brisbane, Singapore, Toronto 1999.
5. Behr, M. A., Wilson, M. A., Gill, W. P., Salamon, H., Schoolnik, G. K., Rane, S., Small, P. M.: Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 284, 1520-1523 (1999).
6. Belisle, J. T., Vissa, V. D., Sievert, T., Takayama, K., Brennan, P. J., Besra, G. S.: Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science 276, 1420-1422 (1997).
7. Berthet, F. X., Lagranderie, M., Gounon, P., Laurent-Winter, C., Ensergueix, D., Chavarot, P., Thouron, F., Maranghi, E., Pelicic, V., Portnoi, D., Marchal, G., Gicquel, B.: Attenuation of virulence by disruption of the Mycobacterium tuberculosis erp gene. Science 282, 759-762 (1998).
8. Bloom, B. R., Fine, P. E.: The BCG experience: implications for future vaccines against tuberculosis. In: Tuberculosis: Pathogenesis, Protection and Control. (B. R. Bloom, ed.), pp. 531-557. ASM Press, Washington, D.C. 1994.
9. Brandt, L., Feino Cunha, J., Weinreich Olsen, A., Chilima, B., Hirsch, P., Appelberg, R., Andersen, P.: Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect. Immun. 70, 672-678 (2002).
10. Bretscher, P. A.: A strategy to improve the efficacy of vaccination against tuberculosis and leprosy. Immunol. Today 13, 342-345 (1992).
11. Brightbill, H. D., Libraty, D. H., Krutzki, S. R., Yang, R. B., Belisle, J. T., Bleharski, J. R., Maitland, M., Norgard, M. V., Plevy, S. E., Smale, S. T., Brennan, P. J., Bloom, B. R., Godowski, P. J., Modlin, R. L.: Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science 285, 732-736 (1999).
12. Brosch, R., Pym, A. S., Gordon, S. V., Cole, S. T.: The evolution of mycobacterial pathogenicity: clues from comparative genomics. Trends Microbiol. 9, 452-458 (2001).
13. Calmette, A., Guerin, C., Negre, L., Bocquet, A.: Sur la vaccination préventive des enfants nouveau-nés contre la tuberculose par le BCG. Ann. Inst. Pasteur. 3, 201 (1927).
14. Chambers, M. A., Williams, A., Gavier-Widen, D., Whelan, A., Hall, G., Marsh, P. D., Bloom, B. R., Jacobs, W. R., Hewinson, R. G.: Identification of a Mycobacterium bovis BCG auxotrophic mutant that protects guinea pigs against M. bovis and hematogenous spread of Mycobacterium tuberculosis without sensitization to tuberculin. Infect. Immun. 68, 7094-7099 (2000).
15. Colditz, G. A., Brewer, T. F., Berkey, C. S., Wilson, M. E., Burdick, E., Fineberg, H. V., Mosteller, F.: Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271, 698-702 (1994).
16. Cole, S. T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., Gordon, S. V., Eiglmeier, K., Gas, S., Barry, C. E., 3rd, Tekaia, F., Badcock, K., Basham, D., Brown, D., Chillingworth, T., Connor, R., Davies, R., Devlin, K., Feltwell, T., Gentles, S., Hamlin, N., Holroyd, S., Hornsby, T., Jagels, K., Barrell, B. G., et al.: Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393, 537-544 (1998).
17. Cole, S. T.: Learning from the genome sequence of Mycobacterium tuberculosis H37Rv. FEBS Lett. 452, 7-10 (1999).
18. Connell, N. D., Medina-Acosta, E., McMaster, W. R., Bloom, B. R., Russell, D. G.: Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guerin expressing the Leishmania surface proteinase Gp63. Proc. Natl. Acad. Sci. USA 90, 11473-11477 (1993).
19. Conradt, P., Hess, J., Kaufmann, S. H. E.: Cytolytic T-cell responses to human dendritic cells and macrophages infected with Mycobacterium bovis BCG and recombinant BCG secreting listeriolysin. Microbes Infect. 1, 753-764 (1999).
20. Duda, R. B., Yang, H., Dooley, D. D., Abu-Jawdeh, G.: Recombinant BCG therapy suppresses melanoma tumor growth. Ann. Surg. Oncol. 2, 542-549 (1995).
21. Edelman, R., Palmer, K., Russ, K. G., Secrest, H. P., Becker, J. A., Bodison, S. A., Perry, J. G., Sills, A. R., Barbour, A. G., Luke, C. J., Hanson, M. S., Stover, C. K., Burlein, J. E., Bansal, G. P., Connor, E. M., Koenig, S.: Safety and immunogenicity of recombinant Bacille Calmette-Guerin (rBCG) expressing Borrelia burgdorferi outer surface protein A (OspA) lipoprotein in adult volunteers: a candidate Lyme disease vaccine. Vaccine 17, 904-914 (1999).
22. Elsasser-Beile, U., Gutzeit, O., Bauer, S., Katzenwadel, A., Schultze-Seemann, W., Wetterauer, U.: Systemic and local immunomodulatory effects of intravesical BCG therapy in patients with superficial urinary bladder carcinomas. J. Urol. 163, 296-299 (2000).
23. Falero-Diaz, G., Challacombe, S., Banerjee, D., Douce, G., Boyd, A., Ivanyi, J.: Intranasal vaccination of mice against infection with Mycobacterium tuberculosis. Vaccine 18, 3223-3229 (2000).
24. Fennelly, G. J., Flynn, J. L., ter Meulen, V., Liebert, U. G., Bloom, B. R.: Recombinant bacille Calmette-Guerin priming against measles. J. Infect. Dis. 172, 698-705 (1995).
25. Fine, P. E.: BCG: the challenge continues. Scand. J. Infect. Dis. 33, 243-245 (2001).
26. Fine, P. E., Carneira, I. A. M., Milstien, J. B., Clements, C. J.: Issues relating to the use of BCG in immunization programmes. World Health Organization, Geneva (1999).
27. Flynn, J. L., Goldstein, M. M., Triebold, K. J., Koller, B., Bloom, B. R.: Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc. Natl. Acad. Sci. USA 89, 12013-12017 (1992).
28. Galen, J. E., Levine, M. M.: Can a "flawless" live vector vaccine strain be engineered? Trends Microbiol. 9, 372-376 (2001).
29. Gheorghiu, M., Lagranderie, M. R., Gicquel, B. M., Leclerc, C. D.: Mycobacterium bovis BCG priming induces a strong potentiation of the antibody response induced by recombinant BCG expressing a foreign antigen. Infect. Immun. 62, 4287-4295 (1994).
30. Good, R. C.: Biology of the mycobacterioses. Simian tuberculosis: immunologic aspects. Ann. N. Y. Acad. Sci. 154, 200-213 (1968).
31. Gordon, S. V., Brosch, R., Billaut, A., Garnier, T., Eiglmeier, K., Cole, S. T.: Identification of variable regions in the genomes of tubercle bacilli using bacterial artificial chromosome arrays. Mol. Microbiol. 32, 643-655 (1999).
32. Grode, L., Kursar, M., Fensterle, J., Kaufmann, S. H. E., Hess, J.: Cell-mediated immunity induced by recombinant Mycobacterium bovis Bacille Calmette-Guerin strains against an intracellular bacterial pathogen: importance of antigen secretion or membrane-targeted antigen display as lipoprotein for vaccine efficacy. J. Immunol. 168, 1869-1876 (2002).
33. Guleria, I., Teitelbaum, R., McAdam, R. A., Kalpana, G., Jacobs, W. R., Bloom, B. R.: Auxotrophic vaccines for tuberculosis. Nat. Med. 2, 334-337 (1996).
34. Hayward, C. M., O'Gaora, P., Young, D. B., Griffin, G. E., Thole, J., Hirst, T. R., Castello-Branco, L. R., Lewis, D.J.: Construction and murine immunogenicity of recombinant Bacille Calmette Guerin vaccines expressing the B subunit of Escherichia coli heat labile enterotoxin. Vaccine 17, 1272-1281 (1999).
35. Hess, J., Miko, D., Catic, A., Lehmensiek, V., Russell, D. G., Kaufmann, S. H.: Mycobacterium bovis Bacille Calmette-Guerin strains secreting listeriolysin of Listeria monocytogenes. Proc. Natl. Acad. Sci. USA 95, 5299-5304 (1998).
36. Himmelrich, H., Lo-Man, R., Winter, N., Guermonprez, P., Sedlik, C., Rojas, M., Monnaie, D., Gheorghiu, M., Lagranderie, M., Hofnung, M., Gicquel, B., Clement, J. M., Leclerc, C.: Immune responses induced by recombinant BCG strains according to level of production of a foreign antigen: malE. Vaccine 18, 2636-2647 (2000).
37. Honda, M., Matsuo, K., Nakasone, T., Okamoto, Y., Yoshizaki, H., Kitamura, K., Sugiura, W., Watanabe, K., Fukushima, Y., Haga, S.: Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guerin vector candidate vaccine for human immunodeficiency virus type 1 in small animals. Proc. Natl. Acad. Sci. USA 92, 10693-10697 (1995).
38. Horwitz, M. A., Harth, G., Dillon, B. J., Maslesa-Galic, S.: Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc. Natl. Acad. Sci. USA 97, 13853-13858 (2000).
39. Horwitz, M. A, Lee, B. W., Dillon, B. J., Harth, G.: Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA 92, 1530-1534 (1995).
40. Huebner, R. E.: BCG vaccination in the control of tuberculosis. In: Current Topics in Microbiology and Immunology 215 AD, pp. 263-282. Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta 30333, USA 1996.
41. Inaba, K., Inaba, M., Naito, M., Steinman, R. M.: Dendritic cell progenitors phagocytose particulates, including bacillus Calmette-Guerin organisms, and sensitize mice to mycobacterial antigens in vivo. J. Exp. Med. 178, 479-488 (1993).
42. Jabbar, I. A., Fernando, G. J., Saunders, N., Aldovini, A., Young, R., Malcolm, K., Frazer, I. H.: Immune responses induced by BCG recombinant for human papillomavirus L1 and E7 proteins. Vaccine 18, 2444-2453 (2000).
43. Jungblut, P., Schaible, U., Mollenkopf, H.J., Zimny-Arndt, U., Raupach, B., Mattow, J., Halada, P., Lamer, S., Hagens, K., Kaufmann, S. H. E.: Comparative proteome analysis of Mycobacterium tuberculosis and Mycobacterium bovis BCG strains: towards functional genomics of microbial pathogens. Mol. Microbiol. 33, 1103-1117 (1999).
44. Kameoka, M., Nishino, Y., Matsuo, K., Ohara, N., Kimura, T., Yamazaki, A., Yamada, T., Ikuta, K.: Cytotoxic T lymphocyte response in mice induced by a recombinant BCG vaccination which produces an extracellular alpha antigen fused with the human immunodeficiency virus type 1 envelope immunodominant domain in the V3 loop. Vaccine 12, 153-158 (1994).
45. Kaufmann, S. H. E.: Immunity to intracellular bacteria. In: Fundamental Immunology. (W. E. Paul, ed.), pp. 1335-1371. Lippincott-Raven, Philadelphia 1998.
46. Kremer, L., Dupre, L., Riveau, G., Capron, A., Locht, C.: Systemic and mucosal immune responses after intranasal administration of recombinant Mycobacterium bovis bacillus Calmette-Guerin expressing glutathione S-transferase from Schistosoma haematobium. Infect. Immun. 66, 5669-5676 (1998).
47. Kremer, L., Riveau, G., Baulard, A., Capron, A., Locht, C.: Neutralizing antibody responses elicited in mice immunized with recombinant bacillus Calmette-Guerin producing the Schistosoma mansoni glutathione S-transferase. J. Immunol. 156, 4309-4317 (1996).
48. Ladel, C. H., Hess, J., Daugelat, S., Mombaerts, P., Tonegawa, S., Kaufmann, S. H. E.: Contribution of alpha/beta and gamma/delta T lymphocytes to immunity against Mycobacterium bovis bacillus Calmette Guerin: studies with T cell receptor-deficient mutant mice. Eur. J. Immunol. 25, 838-846 (1995).
49. Lagranderie, M., Balazuc, A. M., Gicquel, B., Gheorghiu, M.: Oral immunization with recombinant Mycobacterium bovis BCG simian immunodeficiency virus nef induces local and systemic cytotoxic T lymphocyte responses in mice. J. Virol. 71, 2303-2309 (1997).
50. Lagranderie, M., Ravisse, P., Marchal, G., Gheorghiu, M., Balasubramanian, V., Weigeshaus, E. H., Smith, D. W.: BCG-induced protection in guinea pigs vaccinated and challenged via the respiratory route. Tuber. Lung. Dis. 74, 38-46 (1993).
51. Langermann, S., Palaszynski, S. R., Burlein, J. E., Koenig, S., Hanson, M. S., Briles, D. E., Stover, C. K.: Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guerin vaccines expressing pneumococcal surface protein A. J. Exp. Med. 180, 2277-2286 (1994a).
52. Langermann, S., Palaszynski, S., Sadziene, A., Stover, C. K., Koenig, S.: Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorferi. Nature 372, 552-555 (1994b).
53. Lee, M. H., Pascopella, L., Jacobs, W. R., Jr., Hatfull, G. F.: Site-specific integration of mycobacteriophage L5: integration-proficient vectors for Mycobacterium smegmatis, Mycobacterium tuberculosis, and bacille Calmette-Guerin. Proc. Natl. Acad. Sci. USA 88, 3111-3115 (1991).
54. Leung, N. J., Aldovini, A., Young, R., Jarvis, M. A., Smith, J. M., Meyer, D., Anderson, D. E., Carlos, M. P., Gardner, M. B., Torres, J. V.: The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env, and Nef proteins. Virology 268, 94-103 (2000).
55. Lim, E. M., Lagranderie, M., Le Grand, R., Rauzier, J., Gheorghiu, M., Gicquel, B., Winter, N.: Recombinant Mycobacterium bovis BCG producing the N-terminal half of SIVmac251 Env antigen induces neutralizing antibodies and cytotoxic T lymphocyte responses in mice and guinea pigs. AIDS Res. Hum. Retrovir. 13, 1573-1581 (1997).
56. Luo, Y., Chen, X., Han, R., O'Donnell, M. A.: Recombinant bacille Calmette-Guerin (BCG) expressing human interferon-alpha 2B demonstrates enhanced immunogenicity. Clin. Exp. Immunol. 123, 264-270 (2001).
57. Mahairas, G. G., Sabo, P. J., Hickey, M. J., Singh, D. C., Stover, C. K.: Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J. Bacteriol. 178, 1274-1282 (1996).
58. Matsumoto, S., Yukitake, H., Kanbara, H., Yamada, T.: Recombinant Mycobacterium bovis bacillus Calmette-Guerin secreting merozoite surface protein 1 (MSP1) induces protection against rodent malaria parasite infection depending on MSP1-stimulated interferon gamma and parasite-specific antibodies. J. Exp. Med. 188, 845-854 (1998).
59. Miyaji, E. N., Mazzantini, R. P., Dias, W. O., Nascimento, A. L., Marcovistz, R., Matos, D. S., Raw, I., Winter, N., Gicquel, B., Rappuoli, R., Leite, L. C.: Induction of neutralizing antibodies against diphtheria toxin by priming with recombinant Mycobacterium bovis BCG expressing CRM(197), a mutant diphtheria toxin. Infect. Immun. 69, 869-874 (2001).
60. Moreira, A. L., Tsenova, L., Aman, M. H., Bekker, L. G., Freeman, S., Mangliso, B., Schroder, U., Jagirdar, J., Rom, W. N., Tovey, M. G., Freedman, V. H., Kaplan, G.: Mycobacterial antigens exacerbate disease manifestations in Mycobacterium tuberculosis-infected mice. Infect. Immun. 70, 2100-2107 (2002).
61. Murray, A., Winter, N., Lagranderie, M., Hill, D. F., Rauzier, J., Timm, J., Leclerc, C., Moriarty, K. M., Gheorghiu, M., Gicquel, B.: Expression of Escherichia coli beta-galactosidase in Mycobacterium bovis BCG using an expression system isolated from Mycobacterium paratuberculosis which induced humoral and cellular immune responses. Mol. Microbiol. 6, 3331-3342 (1992).
62. Murray, P. J., Aldovini, A., Young, R. A.: Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guerin strains that secrete cytokines. Proc. Natl. Acad. Sci. USA 93, 934-939 (1996).
63. Nascimento, I. P., Dias, W. O., Mazzantini, R. P., Miyaji, E. N., Gamberini, M., Quintilio, W., Gebara, V. C., Cardoso, D. F., Ho, P. L., Raw, I., Winter, N., Gicquel, B., Rappuoli, R., Leite, L. C.: Recombinant Mycobacterium bovis BCG expressing pertussis toxin subunit S1 induces protection against an intracerebral challenge with live Bordetella pertussis in mice. Infect. Immun. 68, 4877-4883 (2000).
64. Neyrolles, O., Gould, K., Gares, M. P., Brett, S., Janssen, R., O'Gaora, P., Herrmann, J. L., Prevost, M. C., Perret, E., Thole, J. E., Young, D.: Lipoprotein access to MHC class I presentation during infection of murine macrophages with live mycobacteria. J. Immunol. 166, 447-457 (2001).
65. Parrish, N. M., Dick, J. D., Bishai, W. R.: Mechanisms of latency in Mycobacterium tuberculosis. Trends Microbiol. 6, 107-112 (1998).
66. Pelicic, V., Jackson, M., Reyrat, J. M., Jacobs, W. R., Gicquel, B., Guilhot, C.: Efficient allelic exchange and transposon mutagenesis in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA 94, 10955-10960 (1997).
67. Power, C. A., Wei, G., Bretscher, P. A.: Mycobacterial dose defines the Th1/Th2 nature of the immune response independently of whether immunization is administered by the intravenous, subcutaneous, or intradermal route. Infect. Immun. 66, 5743-5750 (1998).
68. Scharkoff, H.: Evaluation of tuberculosis control in the region of the former East Germany 1945-1990. Öffentl. Gesundheitswes. 53, 510-513 (1991).
69. Schnorr, R.: Status and perspectives of preventive tuberculosis vaccination in East Germany 1990. Z. Ärztl. Fortbild. 84, 351-354 (1990).
70. Stover, C. K., Bansal, G. P., Hanson, M. S., Burlein, J. E., Palaszynski, S. R., Young, J. F., Koenig, S., Young, D. B., Sadziene, A., Barbour, A. G.: Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine. J. Exp. Med. 178, 197-209 (1993).
71. Stover, C. K., Fuerst, T. R., Burlein, J. E., Benson, L. A., Bennett, L. T., Bansal, G. P., Young, J. F., Lee, M. H., Hatfull, G. F.: New use of BCG for recombinant vaccines. Nature 351, 456-460 (1991).
72. Streit, J. A., Recker, T. J., Donelson, J. E., Wilson, M. E.: BCG expressing LCR1 of Leishmania chagasi induces protective immunity in susceptible mice. Exp. Parasitol. 94, 33-41 (2000).
73. Tsenova, L., Bergtold, A., Freeman, V. H., Young, R. A., Kaplan, G.: Tumor necrosis factor alpha is a determinant of pathogenesis and disease progression in mycobacterial infection of the central nervous system. Proc. Natl. Acad. Sci. USA 96, 5657-5662 (1999).
74. Wangoo, A., Brown, I. N., Marshall, B. G., Cook, H. T., Young, D. B., Shaw, R. J.: Bacille Calmette-Guerin (BCG)-associated inflammation and fibrosis: modulation by recombinant BCG expressing interferongamma (IFN-gamma). Clin. Exp. Immunol. 199, 92-98 (2000).
75. Wiker, H. G., Harboe, M.: The antigen 85 complex: a major secretion product of Mycobacterium tuberculosis. Microbiol. Rev. 56, 648-661 (1992).
76. Winter, N., Lagranderie, M., Gangloff, S., Leclerc, C., Gheorghiu, M., Gicquel, B.: Recombinant BCG strains expressing the SIVmac251nef gene induce proliferative and CTL responses against nef synthetic peptides in mice. Vaccine 13, 471-478 (1995).
77. Winter, N., Lagranderie, M., Rauzier, J., Timm, J., Leclerc, C., Guy, B., Kieny, M. P., Gheorghiu, M., Gicquel, B.: Expression of heterologous genes in Mycobacterium bovis BCG: induction of a cellular response against HIV-1 Nef protein. Gene 109, 4-7-54 (1991).
78. World Health Organization. The World Health Report. 2001. World Health Organization, Geneva. 2001.
79. Yamada, H., Matsumoto, S., Matsumoto, T., Yamada, T., Yamashita, U.: Murine IL-2 secreting recombinant Bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT 2. J. Urol. 164, 526-531 (2000).
80. Yasutomi, Y., Koenig, S., Haun, S. S., Stover, C. K., Jackson, R. K., Conard, P., Conley, A. J., Emini, E. A., Fuerst, T. R, Letvin N. L.: Immunization with recombinant BCG-SIV elicits SIV-specific cytotoxic T lymphocytes in rhesus monkeys. J. Immunol. 150, 3101-3107 (1993).
81. Yasutomi, Y., Koenig, S., Woods, R. M., Madsen, J., Wassef, N. M., Alving, C. R., Klein, H. J., Nolan, T. E., Boots, L. J., Kessler, J. A.: A vaccine-elicited, single viral epitope-specific cytotoxic T lymphocyte response does not protect against intravenous, cell-free simian immunodeficiency virus challenge. J. Virol. 69, 2279-2284 (1995).
82. Yeremeev, V. V., Stewart, G. R., Neyrolles, O., Skrabal, K., Avdienko, V. G., Apt, A. S., Young, D. B.: Deletion of the 19-kDa antigen does not alter the protective efficacy of BCG. Tuber. Lung Dis. 80, 243-247 (2000).
83. Young, D. B.: A post-genomic perspective. Nat. Med. 7, 11-13 (2001).
84. Yuan, Y., Crane, D. D., Simpson, R. M., Zhu, Y. Q., Hickey, M. J., Sherman, D. R., Barry, C. E., 3rd.: The 16-kDa alpha-crystallin (Acr) protein of Mycobacterium tuberculosis is required for growth in macrophages. Proc. Natl. Acad. Sci. USA 95, 9578-9583 (1998).
85. Zhu, Y. D., Fennelly, G., Miller, C., Tarara, R., Saxe, I., Bloom, B., McChesney, M.: Recombinant bacille Calmette-Guerin expressing the measles virus nucleoprotein protects infant rhesus macaques from measles virus pneumonia. J. Infect. Dis. 176, 1445-1453 (1997).